Orphan Drug Focus Haffner Associates specializes in orphan product strategies and regulatory guidance, indicating a potential upsell for end-to-end regulatory strategy, FDA/EMA meeting prep, and designation applications to biotech firms pursuing rare disease therapies.

Policy & Advocacy The company connects with patient advocacy groups and interprets regulatory policies globally, presenting an opportunity to offer policy monitoring, advocacy campaigns, and payer landscape analysis services to sponsors seeking broader stakeholder engagement.

Regulatory Readiness With services around pediatric designations, breakthrough therapy designations, and feasibility assessments, there is potential to provide ongoing regulatory intelligence subscriptions, template libraries, and milestone-based advisory retainers.

Clinical Prep Support Haffner aids in meeting materials and clinical study design evaluation, suggesting prospects for CRO-like collaboration, trial planning tools, and FDA/EMA meeting prep packages for early-stage biotech clients.

SMB Focus Revenue is in the low millions with a small team, indicating ripe demand for scalable, high-value advisory services, partner ecosystems, and bundled regulatory packages tailored to small to mid-size biotech firms seeking regulatory and strategic guidance.